Within the arena of public health battles, all eyes are peeled on COVID-19.

But another health crisis looms: a war against drug-resistant infections. And we may not have the weapons to wage the fight.

U.S. Rep. Mike Doyle, D-Forest Hills, has taken notice. He introduced a bill in December that would stoke interest among drug companies in the research in and development of antibiotics to combat stubborn infection.

This bill must be taken seriously by federal lawmakers.

Advertise with us

As proposed, it would restructure federal contracts such that companies would receive an upfront payment in lieu of compensation based on drug production volume. In essence, there would be a reliable funding stream for innovation in that marketplace.

And that marketplace is unique. Typically, pharmaceutical companies tap into the profit incentive, predicting that the costly development of new drugs will pay off following federal approval and a concurrent boost in drug sales. But, when it comes to antibiotics, large volume sales are counterintuitive. Because resistance is a natural outcome, antibiotics are supposed to be used in small quantities and only when needed — a protocol that will avoid the development of what’s commonly known as “superbugs.” So, the supersized payoff for drug companies doesn’t come and the profit motive is dulled.

Jonathan Steckbeck, founder and CEO of Peptilogics, a Pittsburgh biotech company developing solutions to drug-resistant bacterial infections, summed it up for Post-Gazette reporter Daniel Moore: “There’s a mismatch between what you need to charge to make up for the cost of innovation and what you’re actually able to receive.” He estimated the cost of developing and marketing an antibiotic at $1.4 billion.

Meanwhile, the cost of drug-resistant infections, in terms of sickness and loss of life, is staggering. The U.S. Centers for Disease Control and Prevention peg the numbers at 2.8 million illnesses and more than 35,000 deaths annually. The United Nations reported last year that the number of worldwide deaths from drug-resistant diseases could hit 10 million annually by 2050.

The U.N. report described a future in which common diseases, including respiratory and urinary tract infections and sexually transmitted diseases, would lack a treatment and medical procedures would become riskier.

Advertise with us

Mr. Doyle’s PASTEUR Act, which was introduced with Rep. Drew Ferguson, a Republican from Georgia, would not only restructure the federal payment protocol, it also would boost data collection by hospitals which would receive federal funding for participating in an anti-overuse program.

The pandemic siege has spurred a worldwide response that produced vaccines in record time. Superbugs must be attacked with similar vigor and commitment, and our federal government can help.